Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–18 of 18 trials
Active filters
Clinical trials found
Published and searchable clinical trials
Searching for clinical trials...
NCT06524544
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Locally Advanced Urothelial Carcinoma, +5 more
- Locations
-
- Cancer Center at Saint Joseph's Phoenix, Arizona, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
NCT05269381
- Conditions
- Adenocarcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, +165 more
- Locations
-
- Mayo Clinic in Florida Jacksonville, Florida, United States
NCT07048457
- Conditions
- Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma
- Locations
-
- Yale University New Haven, Connecticut, United States
NCT06265285
- Conditions
- Adenocarcinoma, Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, +81 more
- Locations
-
- Mayo Clinic in Florida Jacksonville, Florida, United States
NCT04878029
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, +6 more
- Locations
-
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
NCT07492628
- Conditions
- Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +17 more
- Locations
-
- Peking University Shenzhen Hospital Shenzhen, Guangdong, China
Active, Not Recruiting
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03244384
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Localized Renal Pelvis and Ureter Urothelial Carcinoma, +19 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
Active, Not Recruiting
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
NCT03854474
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +16 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
- Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut, United States
Active, Not Recruiting
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
NCT04963153
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +36 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- Moffitt Cancer Center Tampa, Florida, United States
Active, Not Recruiting
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
NCT05154994
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, +6 more
- Locations
-
- Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
Active, Not Recruiting
ARID1A and/or KDM6A Mutation and CXCL13 Expression
NCT04953104
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +48 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04637594
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Locally Advanced Bladder Urothelial Carcinoma, +12 more
- Locations
-
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
Active, Not Recruiting
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
NCT05923190
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Locally Advanced Urothelial Carcinoma, +5 more
- Locations
-
- Fox Chase Cancer Center - Philadelphia Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
NCT04007744
- Conditions
- Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +49 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
Active, Not Recruiting
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
NCT04848519
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +30 more
- Locations
-
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
Active, Not Recruiting
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Locally Advanced Urothelial Carcinoma, +5 more
- Locations
-
- University of California San Francisco HDFCCC ( Site 4044) San Francisco, California, United States
- University of Chicago Medical Center ( Site 4037) Chicago, Illinois, United States
- Indiana University Melvin and Bren Simon Cancer Center ( Site 4011) Indianapolis, Indiana, United States
- Dana-Farber Cancer Institute ( Site 4047) Boston, Massachusetts, United States
Active, Not Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552
- Conditions
- Advanced Solid Tumor, Advanced Urothelial Carcinoma, Bladder Cancer, +31 more
- Locations
-
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- UMass Memorial Medical Center Worchester, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center (MSKCC) New York, United States
- Duke Cancer Institute (DCI) - Duke Cancer Center Durham, North Carolina, United States
Active, Not Recruiting
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
NCT00365157
- Conditions
- Advanced Urothelial Carcinoma, Carcinoma, Carcinoma, Transitional Cell, +9 more
- Locations
-
- Tower Cancer Research Foundation Beverly Hills, California, United States
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- City of Hope Antelope Valley Lancaster, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States